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Abstract
Human T-cell leukemia virus type-1 (HTLV-1) is estimated to infect 15–25 million people worldwide, with several areas
including southern Japan and the Caribbean basin being endemic. The virus is the etiological agent of debilitating and fatal
diseases, for which there is currently no long-term cure. In the majority of cases of leukemia caused by HTLV-1, only a single
viral gene, hbz, and its cognate protein, HBZ, are expressed and their importance is increasingly being recognized in the
development of HTLV-1-associated disease. We hypothesized that HBZ, like other HTLV-1 proteins, has properties and
functions regulated by post-translational modifications (PTMs) that affect specific signaling pathways important for disease
development. To date, PTM of HBZ has not been described. We used an affinity-tagged protein and mass spectrometry
method to identify seven modifications of HBZ for the first time. We examined how these PTMs affected the ability of HBZ
to modulate several pathways, as measured using luciferase reporter assays. Herein, we report that none of the identified
PTMs affected HBZ stability or its regulation of tested pathways.
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Introduction
Human T-cell leukemia virus type 1 (HTLV-1) was the first
human retrovirus discovered to be associated with diseases [1,2]
including the aggressive CD4+ T-cell malignancy, adult T-cell
leukemia (ATL) [3], as well as the neurodegenerative disease
HTLV-1-associated myelopathy/tropical spastic paraparesis, and
other inflammatory diseases [4]. HTLV-1 encodes the structural
and enzymatic proteins, Gag, Pol, and Env, as well as the
regulatory proteins, Tax and Rex. The virus also encodes
accessory proteins that are required for efficient infection and
persistence in vivo, but are dispensable for T-cell immortalization
in vitro [5]. The accessory/regulatory protein HBZ is unique in
that it is the only viral protein encoded by the minus strand of the
proviral genome while the rest of the viral proteins are encoded by
the plus strand [6–8]. HBZ is expressed in all HTLV-1 cell lines
and cases of ATL; in fact, in 60% of those ATL cases, hbz is
typically the only viral gene expressed (eg. no Tax) [9]. This
finding is attributed to deletion or hyper-methylation-silencing of
the promoter in the 59 LTR or a non-functional mutation in the
Tax transactivator, which significantly disrupts plus-strand tran-
scription [9,10].
When HBZ was discovered, it was first shown to repress Tax
transactivation of the viral promoter [7,11,12]. Since then, other
functions have been reported such as modulation of the AP-1 [13–
17] and the classical NF-kB signaling pathways [18,19]. More
recent studies have shown that HBZ may regulate the cell-
mediated immune response to the virus infection [20,21]. There
also is growing evidence that HBZ is important in the oncogenic
process since it plays a role in driving infected cell proliferation
[22–24], increasing hTERT transcription [25,26], and inhibiting
apoptosis [20,27].
Post-translational modifications (PTMs) are chemical modifica-
tions added to proteins that can alter many aspects of a protein,
including conformation, localization, and activity. This common
mechanism of cellular regulation is utilized by several pathogens,
including HTLV-1, to alter the expression of their own proteins.
Tax contains several PTMs, for example, phosphorylation of Tax
both stabilizes the protein [28] and inhibits its activity [29]. In
addition, a phosphorylation site is required for the addition of an
acetyl group that activates Tax to enhance NF-kB and induce
transformation [30,31]. Furthermore, our lab has shown phos-
phorylation to be vital for the regulation of Rex function [32].
There currently are no published data about whether HBZ is
post-translationally modified; however, it is known that HBZ
interacts with acetyl-transferases [12,33]. Therefore, we hypoth-
esized that HBZ, like Tax and Rex, would contain PTMs that
regulate important functions. In this study, we purified an affinity-
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tagged-HBZ protein and analyzed this protein by LC-MS/MS. A
high percentage of the protein, including the majority of the key
leucine-zipper domain at the C-terminus, was covered in this
analysis. This approach identified 7 modifications, which were
further characterized by mutational analysis to determine if they
regulated known HBZ functions.
Materials and Methods
Cells
293T cells were maintained in Dulbecco’s modified Eagle’s
medium and Jurkat T-cells were maintained in RPMI medium at
37uC in a humidified atmosphere of 5% CO2 and air. Media was
supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml).
Cells were originally obtained from ATCC.
Plasmids
To generate the Flag-6xHis-HBZ construct, the HBZ cDNA
was inserted downstream of an N-terminal Flag-6xHis affinity tag
and expression was driven by a CMV promoter. Amino acid
exchanges were made using the QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). All mutations were
confirmed by DNA sequencing and expression was verified by
transfection and Western blot analysis. The pCMV-c-Jun and
pLG4-10-6xAP-1-Luc plasmids were graciously provided by Dr.
John C. McDermott of York University. The p65 expression
plasmid and kB-Luc plasmid were a kind gift from Dr. Dean
Ballard of Vanderbilt University. The IRF-1 expression plasmid
and IRF-1 luciferase reporter plasmid were graciously provided by
Dr. John Yim of the Beckman Research Institute.
Protein Purification
293T cells were plated in six 100 mm dishes, three per
condition, and each plate was transfected with 10 mg of empty
vector or Flag-6xHis-HBZ plasmid using lipofectamine (Invitro-
gen, Carlsbad, CA). Twenty-four hours post-transfection, cells
were collected, combined, washed in cold 1x PBS, and lysed
following the FLAG fusion protein immunoprecipitation and SDS-
PAGE buffer elution protocols of the FLAG M Purification Kit
(Sigma Aldrich, St. Louis, MO). Samples were loaded on a large
12% SDS-PA gel and electrophoresed for 3 hours at 55 mA. The
gel was washed with Millipore water and stained using GelCode
Blue Stain (Thermo Scientific, Rockford, IL). The HBZ band was
excised from the gel for further proteomic analysis.
Mass Spectrometry and Proteomic Analysis
LC-MS/MS analysis was performed as described previously
[34] with following modifications. HBZ excised gel slices were cut
into small pieces (2–3 mm cubes) and incubated on a shaker
overnight in 50% acetonitrile to distain gel pieces from Coomassie
dye. Samples were reduced with 7.5 mM DTT in 75 mM
ammonium bicarbonate solution at 50uC for 30 min, after which
DTT was removed and the protein was alkylated with 40 mM
iodoacetamide in 75 mM ammonium bicarbonate solution for
20 min at room temperature in dark. The gel pieces were washed
with acetonitrile, desiccated in a speed-vac. Aliquots were,
subjected to in-gel proteolysis using the following endoproteinases
(5 ng/ml): i) sequencing grade modified trypsin (Promega); ii)
sequencing grade chymotrypsin (Roche); iii) sequencing grade
endoproteinase Asp-N, (Roche) and iv) Trypsin/Asp-N combina-
tion. The resulting peptides were extracted in 100 ml of acetonitrile
by vortexing for 10 min. The solution was transferred to new small
microcentrifuge tubes and desiccated in a speed-vac. Dryed
samples were resuspended in 6 ml buffer A (2% acetonitrile, 0.2%
formic acid,) and 5 ml were separated on a 15 cm60.075 mm
fused silica capillary column packed with reversed phase 3 mm
ReproSil-Pur C18AQ resin (Dr. Maisch GmbH, Ammerbuch-
Entringen, Germany) using a nano EASY HPLC. Peptides were
eluted over 50 min by applying a 0–30% linear gradient of buffer
B (80% acetonitrile, 19.8% water and 0.2% formic acid) at a flow
rate of 350 nL/min. The Orbitrap (Thermo Fischer Scientific,
San Jose, CA) was run in data dependent mode with 10 data-
dependent scan events for each full MS scan. Normalized collision
energy was set at 35, activation Q was 0.250. AGC target for MS
was 16106 and AGC target for MS/MS was 56104. Dynamic
exclusion was set to 60 s and early expiration was disabled.
Sequence analysis was performed with MASCOT (Matrix
Sciences, London GB) software using an indexed human subset
database of Swissprot, supplemented with HTLV, 263 contami-
nants and 114960 decoy sequences.
Reporter Assays
Each functional reporter assay had its own set of conditions for
plasmid concentrations. In brief, 293 T cells were seeded in 6-well
plates at 26105 cells per well. Twenty-four hours post-plating, cells
were transfected with 10 or 20 ng of renilla-TK, a luciferase
reporter, an expression plasmid of a specific transcription factor,
and an HBZ expression plasmid at one of two concentrations (1:5
or 1:10 ratio). Empty vector was added to make the total DNA
concentration equal among all transfections. Transfections were
performed using Lipofectamine (Invitrogen, Carlsbad, CA).
Twenty-four hours post-transfection, cells were collected and
analyzed using a dual luciferase assay kit (Promega, Madison, WI).
Levels of firefly luciferase and renillia luciferase were measured
using a Packard LumiCount luminometer. Each experiment was
performed three independent times in duplicates. Jurkat T-cells
were plated in 6-well dishes at 3.56105 cells per well. Twenty-four
hours post-plating, cells were transfected using TransFectin lipid
reagent (Bio-Rad Laboratories, Hercules, CA) by following the
manufacturer’s guidelines. Forty hours post-transfection, cells
lysates were collected and analyzed as described above.
Western Blot Analysis
Transfected cells were lysed in 1x Passive Lysis Buffer (Promega,
Madison, WI) with protease inhibitor cocktail (Roche, Mannheim,
Germany). Protein concentrations were measured using a Nano-
drop spectrophotometer (Thermo Fisher Scientific, Waltham,
MA). SDS dye (6x solution) was added to the lysates and samples
were boiled for 10 min. Twenty micrograms of protein were
resolved by SDS-PAGE and transferred to nitrocellulose mem-
branes. Blots were probed with a rabbit polyclonal anti-HBZ
antiserum (1:1000), a mouse anti-Flag M2 antibody (1:5000)
(Sigma Aldrich, St. Louis, MO), or mouse anti-Actin (1:10000)
according to standard procedures. Secondary antibodies used
included goat anti-rabbit and goat anti-mouse conjugated with
horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz,
CA) at a dilution of 1:2000. Blots were developed using
Immunocruz luminol reagent (Santa Cruz Biotechnology) and
imaged using the Fuji LAS 4000 imaging system (GE Healthcare
Life Sciences, Piscataway, NJ). Densitometry was measured using
Multi Gauge version 3.0 software (Fujifilm, Tokyo, Japan).
Results
Prediction of HBZ PTMs
There are currently no reports on whether HBZ is post-
translationally modified, but it is well known that PTMs can play a
HTLV-1 HBZ Post-Translational Modifications
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major role in the properties and functions of proteins. Two major
types of modification are phosphorylation and acetylation. These
modifications are reversible and are used to modify the activity of
many transcription factors [35]. Using the online phosphorylation
prediction tool, NetPhos 2.0 Server [36], we found 6 potential
phosphorylation sites on HBZ (Table 1). We also used the online
tool PAIL [37] for acetylation prediction (Table 2) that predicted
16 acetylated lysines. These data suggested that HBZ was likely
modified by the cell. Instead of mutating all predicted modified
residues, we first set out to identify modified residues by
performing mass spectrometry (MS). This approach would allow
us to identify both phosphorylation and acetylation added to HBZ
within a eukaryotic cell in a single assay. This analysis was
dependent on the production and purification of substantial
quantities of HBZ protein.
Function and purification of Flag-6xHis-HBZ
Varying amounts of the Flag-6xHis-HBZ construct were
transfected into 293T cells along with a Tax expression plasmid
and the HTLV-1-LTR-Luciferase reporter plasmid (Figure 1A).
As expected, Flag-6xHis-HBZ was able to repress Tax transactiva-
tion in a dose-dependent manner similarly to untagged, wild-type
HBZ. We next verified that we would be able to adequately purify
HBZ for mass spectrometry analysis. Using components of Sigma’s
FLAG M Purification kit, lysates from HBZ-transfected 293T cells
were collected and HBZ was purified using agarose beads
conjugated with mouse anti-Flag antibody. SDS-PAGE and
GelCode Blue visualization revealed a specific band correlating
to tagged HBZ that could be processed for mass spectrometry
(Figure 1B).
Identification of PTMs
Multiple runs of LC-MS/MS were performed with protein
digestion schemes described in the Materials and Methods section.
Overall, we were able to obtain 68% coverage of the amino acid
sequence, including the majority of the key leucine-zipper
functional domain and identified several PTMs (Figure 2). We
detected phosphorylation on S49, acetylation on K66 and K155,
and methylation on K35, K37, K181 and K186 (Figure 2 and
Tables 1–3). The majority of these modifications occur in the
important protein-protein interaction domains of HBZ. Of the
predicted phosphorylation sites, we covered 5 of the 6 predicted
Table 1. Predicted and Identified Phosphorylation Sites of HBZ.
Predicted Phosphorylation Site Score Threshold Times Modified/Times Detected % Modified
S29 0.974 0.5 0/5 0.00%
S49 0.975 0.5 1/27 3.70%
S54 0.965 0.5 0/15 0.00%
T73 0.991 0.5 0/5 0.00%
S150 0.993 0.5 N.D. N/A
S174 0.929 0.5 0/87 0.00%
N.D. means Not Detected. N/A means Not Applicable.
doi:10.1371/journal.pone.0112762.t001
Table 2. Predicted and Identified Acetylation Sites of HBZ.
Predicted Acetylation Site Score Threshold Times Modified/Times Detected % Modified
K66 2.09 0.5 39/39 100.00%
K84 2.64 0.5 N.D. N/A
K86 1.65 0.5 N.D. N/A
K88 2.42 0.5 N.D. N/A
K89 1.96 0.5 N.D. N/A
K93 1.47 0.5 0/2 0.00%
K106 0.79 0.5 N.D. N/A
K110 1.37 0.5 N.D. N/A
K119 1.51 0.5 N.D. N/A
K120 2.43 0.5 0/1 0.00%
K128 0.75 0.5 N.D. N/A
K145 1.6 0.5 N.D. N/A
K147 1.89 0.5 N.D. N/A
K153 1.26 0.5 N.D. N/A
K155 1.13 0.5 2/71 2.82%
K181 0.67 0.5 0/73 0.00%
N.D. means Not Detected. N/A means Not Applicable.
doi:10.1371/journal.pone.0112762.t002
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sites (Table 1), and 5 of the 16 predicted acetylation sites (Table 2).
We compared MS spectrum counts for modified peptides with
their unmodified counterparts, which allowed semiquantitative
analysis for the frequency of modifications (Tables 1–3). Our data
suggest that the phosphorylation of HBZ is an infrequent
occurrence since S49 showed limited phosphorylation. The
addition of an acetyl group to K155 also seems to be a rare
event, being detected approximately 3% of the time. Of the
Figure 1. Flag-6xHis-tagged HBZ represses Tax transactivation
and can be purified. (A) The functional activity of Flag-6xHis-HBZ was
determined by measuring its ability to repress Tax trans-activation of a
LTR1-luc reporter in 293T cells. Cells were transfected with S-tag Tax
(200 ng), LTR-1 luciferase reporter (100 ng) renilla-TK (20 ng) and a
titration of HBZ constructs (100 and 500 ng.) Values represent mean
measurements relative to Tax expression alone. Error bars represent
standard deviation. Western blots were performed on 20 ug total cell
lysate and probed with rabbit HBZ-specific antisera. Actin was used as a
loading control. (B) Flag-6xHis-HBZ was purified from lysates of
transfected 293T cells using agarose beads conjugated with anti-Flag
antibody. Bands were resolved by SDS-PAGE and the gel was stained
with GelCode Blue.
doi:10.1371/journal.pone.0112762.g001
Figure 2. MS based analysis of PTMs in HBZ. (A) MS/MS
fragmentation of HBZ peptide DGLLSLEEELK*, where Lys is methylated.
(B) MS/MS Fragmentation of HBZ peptide GPPGEK*APPR, where Lys is
acetylated. (C) MS/MS Fragmentation of HBZ peptide DGLLS*LEEESR,
where Ser is phosphorylated. (D) Summary of MS results. The HBZ
sequence is provided, with covered sequences underlined. PTMs found
are highlighted in the sequence and marked relative to the three
domains of HBZ in a cartoon.
doi:10.1371/journal.pone.0112762.g002
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discovered methylations, our data indicate that only K35 is
methylated with some consistency. Furthermore, we provide
evidence that K66 is constitutively acetylated, neutralizing the
positive charge of this amino acid. All these identified modifica-
tions are novel and, we hypothesized, could regulate the properties
and/or functions of HBZ.
PTMs do not affect HBZ steady-state levels
In the current study, we decided to examine the roles of
phosphorylation and acetylation individually by mutating modi-
fied amino acids to mimetic (SRD and KRQ, respectively) and
inhibitory (SRA and KRR, respectively) residues for each PTM.
We also created a phospho-, acetyl-mimetic mutant (PhAc-mim:
S49D-K66Q-K155Q), and a phospho-, acetyl-inhibitory mutant
(PhAc-inh: S49A-K66R-K155R) for the discovered modified sites
to investigate if they act in concert. The approach of having
mimetic and inhibitory mutants allowed us to compare each
mutant to the wild-type protein and the paired residue mutation. It
also is important to examine both the mimetic and inhibitory
mutations as both phosphorylation and acetylation can positively
or negatively regulate the functions of proteins. We decided not to
focus on the discovered methylation sites currently since all
methylated states were found in less than half the cases of detected
peptides and we cannot create a methylated lysine mimetic
mutation. If future studies identify methyltransferases that interact
with HBZ, it would be interesting to see if over-expression of these
enzymes modifies these residues of HBZ and are important for
HBZ function.
After the creation of the mutant forms of HBZ in the Flag-6xHis
vector, Western blot analysis was performed to examine if any of
the modifications affected the steady-state levels of the protein. We
hypothesized that acetylation of K66 would be important for
protein stability as it was found to be constitutively modified.
However, probing for the affinity-tag showed that none of the
modifications affected the steady state level of the protein
(Figure 3).
PTMs do not affect inhibition of viral regulatory proteins
HBZ inhibits Tax-transactivation of the LTR promoter by
binding to the co-activators CREB and p300 [11,12] and by up-
regulating the ubiquitin E3 ligase PDLIM2, which targets Tax for
degradation [38]. To examine if the phosphorylation and
acetylation of HBZ were important for this function, 293 T cells
were transfected with an HTLV-1 LTR-luciferase reporter along
with Tax and titrating amounts of wild-type HBZ, the PTM
mutants, and a DLZ mutant (previously shown to repress Tax-
transactivation to a lesser extent than wild-type) [11,12]
(Figure 4A). As expected, wild-type HBZ and, to a lesser degree,
HBZDLZ, were able to repress Tax trans-activation of the HTLV-
1 LTR promoter. We observed that all PTM mutants tested were
able to inhibit Tax activity to a similar degree as wild-type HBZ
and found no significant difference between paired mutants. It
should be noted that this result for the S49 mutants was not
unexpected because these mutations were reported previously to
bind to p300, inhibiting it from interacting with Tax [12]. To
examine if the PTMs affected HBZ’s functions within a T-cell, the
luciferase assay was repeated in Jurkat T-cells (Figure 4B). Results
in Jurkat T-cells were similar to 293 T cells; all the tested PTM
mutants functioned similarly to wild-type HBZ and repressed Tax-
transactivation of the HTLV-1 LTR promoter. These data suggest
that the tested PTMs do not affect the ability of HBZ to modulate
Tax activity. More recently, it has been reported that HBZ
modestly repressed Rex function in a dose-dependent manner in
HeLa cells [39]. We confirmed this repression of Rex activity by
wild-type HBZ and that all of the PTM mutants functioned
similarly to wild-type HBZ (data not shown). These data suggest
that the tested PTMs do not affect the ability of HBZ to modulate
Rex activity.
Table 3. Detected Methylation Sites of HBZ.
Methylated Residue Times Modified/Times Detected % Modified
K35 3/10 30.00%
K37 1/6 16.67%
K181 3/73 4.11%
K186 1/80 1.25%
doi:10.1371/journal.pone.0112762.t003
Figure 3. Steady-state levels of HBZ protein is not altered by identified PTMs. Lysates were collected from transfected 293 T cells and were
resolved by SDS-PAGE. The amount of lysate loaded was normalized to measured renilla-TK values. The blot was probed with mouse anti-Flag M2
(1:5000). Densitometries were measured and the ratios are reported under the blot.
doi:10.1371/journal.pone.0112762.g003
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PTMs of HBZ do not affect p65 or c-Jun transcriptional
activity
It previously was reported that HBZ represses the classical NF-
kB pathway by inhibiting the DNA-binding of p65 and inducing
p65 degradation [18]. This finding was important because this
binding stopped cells from entering Tax-induced senescence [19].
We used a reporter assay to examine if the discovered PTMs
affected the ability of HBZ to repress p65 in both 293 T cells and
Jurkat T-cells (Figure 5A and 5B). These data demonstrated that
the PTMs of HBZ, individually and in combination with each
other, did not affect HBZ’s ability to repress p65 transcriptional
activity in either cell type.
We next examined how the PTMs affect the ability of HBZ to
repress c-Jun transcriptional activity because HBZ and APH-2, the
HBZ counterpart in non-pathogenic HTLV-2, differentially
regulate this cellular pathway [13,40]. 293 T cells were transfected
with a 6xAP-1-luciferase construct along with pCMV-c-Jun and
titrating amounts of HBZ. Because HBZ interacts with c-Jun
through its leucine zipper domain [13], we also included the
HBZDLZ mutant (Figure 6). Our results show WT HBZ was able
to repress c-Jun-mediated transcription and the HBZDLZ mutant
was unable to repress c-Jun. All PTM mutants acted in a manner
similar to WT HBZ, indicating none of the PTMs affected the
interaction of HBZ with c-Jun. Taken together, our data indicate
that the phosphorylation and acetylation state at these residues are
not important for the ability of HBZ to modulate the classical NF-
kB and AP-1 pathways.
Figure 4. Phosphorylation and acetylation do not alter the ability of HBZ to repress Tax transactivation of the LTR promoter. (A)
293 T cells were transfected with LTR-1-luc reporter (100 ng), renilla-TK (20 ng), S-tagged Tax (200 ng) and a titration of HBZ mutants (100 ng and
500 ng). DNA amounts were normalized with empty Flag-6xHis plasmid. Twenty-four hours post-transfection, lysates were collected and luciferase
levels were measured. (B) Jurkat T-cells were transfected with LTR-1-luc reporter (300 ng), renilla-TK (100 ng), S-tagged Tax (600 ng) and HBZ mutants
(1500 ng). Forty hours post-transfection, lysates were collected and luciferase levels were measured. Error bars represent standard deviations.
doi:10.1371/journal.pone.0112762.g004
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Repression of IRF-1 is not dependent on HBZ PTMs
After testing whether PTMs regulate the ability of HBZ to
repress viral expression and growth pathways, we next turned our
attention to a component of the innate immune system. Interferon
(IFN) regulatory factors (IRFs) are key components of the immune
system as they control interferon production and development of
immune cells, but they also play a role in regulating oncogenesis
[41]. IRF-1 induces the expression of type-I IFN and acts as a
tumor suppressor by inducing apoptosis [42]. Clinical data have
shown that IRF-1 expression is lost in many cases of leukemia [43].
Since HBZ is typically the only HTLV-1 protein expressed in
cases of ATL, Mukai et al investigated if HBZ and IRF-1
interacted [20]. They discovered that the N-terminus of HBZ was
important for binding IRF-1 and repressing its activity. We
performed a reporter assay to assess whether the PTMs of HBZ
regulated the repression of IRF-1 transcriptional activity (Fig-
ure 7). All PTM mutants were able to repress IRF-1 in a dose-
dependent manner and there were no significant differences
between paired mutations. These data suggest that PTMs are not
involved in the regulation of IRF-1 activity by HBZ.
Discussion
Our present research is the first to report PTMs of HBZ and to
define the potential role of these PTMs in the known functions of
HBZ. Using online prediction tools, we found 6 potential sites of
phosphorylation and 16 sites of acetylation. Our MS data covered
68% of the amino acids of HBZ, including 5 of the 6 potential
phosphorylation sites and 5 of the 16 acetylation sites. In total, 7
Figure 5. Phosphorylation and acetylation do not affect the ability of HBZ to repress p65-mediated transcription. (A) 293 T cells were
transfected with kB-luc reporter (100 ng), renilla-TK (20 ng), p65 expression plasmid (50 ng) and a titration of HBZ constructs (100 ng and 500 ng).
DNA amounts were normalized with empty Flag-6xHis plasmid. Lysates were collected 24 hours post-transfection and luciferase levels were
measured. (B) Jurkat T-cells were transfected with kB-luc reporter (200 ng), renilla-TK (100 ng), p65 expression plasmid (100 ng) and HBZ mutants
(1000 ng). Lysates were collected 40 hours post-transfection and luciferase levels were measured. Error bars represent standard deviations.
doi:10.1371/journal.pone.0112762.g005
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modifications were identified: 1 phosphorylation, 2 acetylations,
and 4 methylations. Three of these modifications occur in the N-
terminal activation domain, one in between the activation domain
and central domain, and the final three occur in the leucine zipper
domain. Only acetylation of K66 occurred at a high frequency,
with the 6 other modifications occurring at low frequency. The
negative predicted sites that were covered cannot be fully ruled out
as being modified, but we are confident that the modifications do
not occur at a high frequency. Of the uncovered predicted sites, it
would seem likely that acetylation would occur more frequently
than phosphorylation because there are more sites available and
HBZ is known to interact with acetyl-transferases.
We first examined the effect that these PTMs had on the steady
state levels of the protein, but found no difference between samples
and controls. We next tested how PTMs affect the ability of HBZ
to repress Tax transactivation. Because none of the mutants acted
Figure 6. Phosphorylation and acetylation do not affect the ability of HBZ to inhibit c-Jun-mediated transcription. 293 T cells were
transfected with a 6xAP-1-luc reporter (50 ng), renilla-TK (10 ng), pCMV-c-Jun (25 ng) and a titration of HBZ constructs (10 ng and 100 ng). DNA
amounts were normalized with empty Flag-6xHis plasmid. Lysates were collected 24 hours post-transfection and luciferase levels were measured.
Error bars represent standard deviations.
doi:10.1371/journal.pone.0112762.g006
Figure 7. The ability of HBZ to repress IRF-1 activity is not affected by the identified PTMs. 293 T cells were transfected with pIRF-1-luc
(50 ng), renilla-TK (20 ng), IRF-1 expression plasmid (100 ng) and a titration of HBZ constructs (50 ng and 500 ng). DNA amounts were normalized
with empty Flag-6xHis plasmid. Lysates were collected 24 hours post-transfection and luciferase levels were measured. Error bars represent standard
deviations.
doi:10.1371/journal.pone.0112762.g007
HTLV-1 HBZ Post-Translational Modifications
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differently than the wild-type at a low or high concentration, we
are able to infer two aspects of the identified phosphorylation and
acetylation: 1) they do not affect the interaction of HBZ with p300,
and 2) they do not affect the interaction of HBZ with CREB. The
cellular signaling pathways AP-1 and NF-kB, along with IRF-1-
mediated transcription were examined. Although the modifica-
tions found were in domains that modulate the activity of the
tested transcription factors, they did not play any role in the ability
of HBZ to repress these selected pathways.
HBZ is known to interact with several proteins and affect
various cellular pathways. While we could not identify any role for
PTMs in the pathways examined, it remains possible that these
PTMs have a function. Although the enzymes that add PTMs to
their cognate proteins within the cell are not 100% specific for
functionality, their promiscuity is still expected to be limited due to
the importance of strict regulation and localization. The possibility
that a combination of identified and unidentified PTMs may be
necessary cannot be ruled out at this point. Furthermore, it is
important to note that there could be unknown functions of HBZ
that are regulated by these three PTMs. Future studies should
focus on modifications that cannot be readily detected by MS such
as SUMOylation [44,45] as these have also been shown to be
important for regulating protein functions.
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